Computational analysis and enzyme assay of inhibitor response to disease single nucleotide polymorphisms (SNPs) in lipoprotein lipase

Lipoprotein lipase (LPL) is the rate-limiting enzyme for the hydrolysis of the triglyceride (TG) core of circulating TG-rich lipoproteins, chylomicrons, and very low-density lipoproteins. The enzyme has been established as an efficacious and safe therapeutic target for the management of obesity. Here, a systematic profile of the lipase inhibitor response of three anti-obesity agents (Orlistat, Lipstatin, and Cetilistat) to clinical LPL missense mutations arising from disease single nucleotide polymorphisms (SNPs) was established by integrating complex structure modeling, virtual mutagenesis, molecular dynamics (MD) simulations, binding energy analysis, and radiolabeled TG hydrolysis assays. The profile was then used to characterize the resistance and sensitivity of systematic mutation-inhibitor pairs. It is suggested that the Orlistat and Lipstatin have a similar response profile to the investigated mutations due to their homologous chemical structures, but exhibit a distinct profile to that of Cetilistat. Most mutations were predicted to have a modest or moderate effect on inhibitor binding; they are located far away from the enzyme active site and thus can only influence the binding limitedly. A number of mutations were found to sensitize or cause resistance for lipase inhibitors by directly interacting with the inhibitor ligands or by indirectly addressing allosteric effect on enzyme active site. Long-term MD simulations revealed a different noncovalent interaction network at the complex interfaces of Orlistat with wild-type LPL as well as its sensitized mutant H163R and resistant mutant I221T.

[1]  Dermot F. Reilly,et al.  Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .

[2]  R. Hegele,et al.  Severe Hypertriglyceridemia due to a novel p.Q240H mutation in the Lipoprotein Lipase gene , 2015, Lipids in Health and Disease.

[3]  E. Menteşe,et al.  Synthesis of Some New 1,2,4‐Triazole Derivatives Starting from 3‐(4‐Chlorophenyl)‐5‐(4‐methoxybenzyl)‐4H‐1,2,4‐triazol with Anti‐Lipase and Anti‐Urease Activities , 2014, Archiv der Pharmazie.

[4]  P. Stenson,et al.  The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine , 2013, Human Genetics.

[5]  ZiYun Wang,et al.  Comparative Analyses of Lipoprotein Lipase, Hepatic Lipase, and Endothelial Lipase, and Their Binding Properties with Known Inhibitors , 2013, PloS one.

[6]  Lijun Liu,et al.  Strain energy in enzyme–substrate binding: An energetic insight into the flexibility versus rigidity of enzyme active site , 2012 .

[7]  Lijun Liu,et al.  Use of QM/MM scheme to reproduce macromolecule–small molecule noncovalent binding energy , 2012 .

[8]  J. Poupaert,et al.  Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors. , 2012, Journal of medicinal chemistry.

[9]  Dima Kozakov,et al.  FTMAP: extended protein mapping with user-selected probe molecules , 2012, Nucleic Acids Res..

[10]  Jing Hu,et al.  SIFT web server: predicting effects of amino acid substitutions on proteins , 2012, Nucleic Acids Res..

[11]  P. Zhou,et al.  Specific noncovalent interactions at protein-ligand interface: implications for rational drug design. , 2012, Current medicinal chemistry.

[12]  Shaoming Yang,et al.  Applying chemometrics approaches to model and predict the binding affinities between the human amphiphysin SH3 domain and its peptide ligands. , 2010, Protein and peptide letters.

[13]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[14]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[15]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[16]  H. Shin,et al.  Association of lipoprotein lipase (LPL) single nucleotide polymorphisms with type 2 diabetes mellitus , 2008, Experimental & Molecular Medicine.

[17]  R. Padwal.  Cetilistat, a new lipase inhibitor for the treatment of obesity. , 2008, Current opinion in investigational drugs.

[18]  Alyce Adams,et al.  Why is the Developed World Obese? , 2007, Annual review of public health.

[19]  Adrian A Canutescu,et al.  SCWRL and MolIDE: computer programs for side-chain conformation prediction and homology modeling , 2008, Nature Protocols.

[20]  J. Dixon,et al.  Obesity management: Update on orlistat , 2007, Vascular health and risk management.

[21]  K. Bhutani,et al.  Pancreatic lipase inhibitors from natural sources: unexplored potential. , 2007, Drug discovery today.

[22]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[23]  Johnf . Thompson,et al.  Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels. , 2004, Biochimica et biophysica acta.

[24]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[25]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[26]  B. Tomlinson,et al.  Pathogenic mutations of the lipoprotein lipase gene in Chinese patients with hypertriglyceridemic type 2 diabetes , 2003, Human mutation.

[27]  A. Sali,et al.  Modeller: generation and refinement of homology-based protein structure models. , 2003, Methods in enzymology.

[28]  D. Ramji,et al.  Lipoprotein lipase: structure, function, regulation, and role in disease , 2002, Journal of Molecular Medicine.

[29]  T. Nakajima,et al.  Molecular modeling of the dimeric structure of human lipoprotein lipase and functional studies of the carboxyl-terminal domain. , 2002, European journal of biochemistry.

[30]  J. Moult,et al.  SNPs, protein structure, and disease , 2001, Human mutation.

[31]  A. Takagi,et al.  A compound heterozygote for a novel missense mutation (G105R) in exon 3 and a missense mutation (D204E) in exon 5 of the lipoprotein lipase gene in a Japanese infant with hyperchylomicronaemia. , 2000, Clinical science.

[32]  E. Takeda,et al.  A newly identified lipoprotein lipase (LPL) gene mutation (F270L) in a Japanese patient with familial LPL deficiency. , 2000, Biochimica et biophysica acta.

[33]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[34]  Junmei Wang,et al.  How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? , 2000, J. Comput. Chem..

[35]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[36]  S. Gehrisch.  Common mutations of the lipoprotein lipase gene and their clinical significance , 1999, Current atherosclerosis reports.

[37]  J. Richardson,et al.  Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. , 1999, Journal of molecular biology.

[38]  J. Brunzell,et al.  Homozygosity for two point mutations in the lipoprotein lipase (LPL) gene in a patient with familial LPL deficiency: LPL(Asp9-->Asn, Tyr262-->His). , 1996, Journal of lipid research.

[39]  M. Hayden,et al.  A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis , 1995, Nature Genetics.

[40]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[41]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[42]  S. Deeb,et al.  Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes. , 1992, Journal of lipid research.

[43]  H. Brewer,et al.  Lipoprotein lipaseBethesda: a single amino acid substitution (Ala-176----Thr) leads to abnormal heparin binding and loss of enzymic activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Emi,et al.  Missense mutation (Gly----Glu188) of human lipoprotein lipase imparting functional deficiency. , 1990, The Journal of biological chemistry.

[45]  P. Hadváry,et al.  Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. , 1987, The Journal of antibiotics.

[46]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .